Heplatinum Pharmaceutical-B (02142) rose nearly 9%. As of press release, it rose 8.94% to HK$1.95, with a turnover of HK$5,516,700.
The Zhitong Finance App learned that Hebo Pharmaceutical-B (02142) rose nearly 9%. As of press release, it had risen 8.94% to HK$1.95, with a turnover of HK$5,516,700.
According to the news, Heplatinum Pharmaceuticals announced yesterday that its bispecific antibody HBM9027 has obtained the US Food and Drug Administration (FDA) New Drug Research Application License (IND) and will launch the first human (FIH) clinical trial in the US. This trial is a phase I study evaluating the safety, tolerability, pharmacokinetics, and antitumor activity of HBM9027 in patients with advanced solid tumors.
In addition, the company recently announced that it expects to make a profit of approximately US$18 million for the year ended December 31, 2023, and a loss of approximately US$137 million for the year ended December 31, 2022. Guoyuan International believes that the company has multiple global patent protected all-human antibody platforms and unique pipelines, and that continuous licensing cooperation will drive the company's future performance growth. The company has always focused on next-generation innovative therapies in the field of immunity and tumor immunity. Its Harbour Mice, HBICE, GPCR drug development, and ADC platforms all have unique advantages.